Fluimucil - Indications
Fluimucil is indicated when it is difficult to expectorate secretions and there is plenty dense and viscous, such as chronic bronchitis and its exacerbations, pulmonary emphysema, bronchitis, smoking, acute bronchitis, pneumonia, lung abscesses, pulmonary atelectasis, cystic fibrosis (inherited disease that produces thick mucus, also known as cystic fibrosis) and others. It is also indicated as an antidote in accidental or deliberate poisoning by paracetamol.
Identified hypersensitivity to N-acetylcysteine.
Patients with asthma should be closely monitored during treatment if bronchospasm occurs, treatment should be stopped immediately. The possible presence of sulphurous odor does not indicate a change in preparation, it is itself the active principle contained in it. Especially at the beginning of acetylcysteine ??treatment is able to thin bronchial secretions, while increasing the volume of the same. If the patient cannot cough effectively, it will be necessary to postural drainage and aspiration, to avoid retention of secretions. Only Fluimucil effervescent tablet: "Warning phenylketonuria: contains phenylalanine" Only Fluimucil Granules 100 mg and 200: "Diabetics: contains sugar." Fluimucil syrup 40 mg / mL contains sorbitol, which when used in excess can cause stomach pain and diarrhea, should be used with caution in diabetic patients. Fluimucil D granules contain 600 mg fructose, and should not be used in patients with hereditary fructose intolerance. This presentation should be used with caution in diabetic patients.
Pregnancy and lactation
Category B: This medication should not be used by pregnant women without medical or dental surgeon. Breastfeeding does not have data on women during breastfeeding, so do not recommend using this medicine during breastfeeding.
The drug interacts with oral antibiotics, so it is recommended to use interspersed between the drugs. We suggest the use of oral Fluimucil 2 hours before or after antibiotic administration. Amoxicillin, doxycycline, cephalexin, orally administered acetylcysteine ??increased the bioavailability of amoxicillin, doxycycline did not alter the absorption and reduced the cephalexin. Ampicillin, when administered concomitantly with acetylcysteine, no change in the bioavailability of ampicillin orally, but there was a small non-significant increase in serum concentration of erythromycin. Findings of laboratory tests, clinically important changes in laboratory parameters default, were not found with the administration of Fluimucil.